11 results on '"Tatiana Shneider"'
Search Results
2. Long-term outcomes of third-line therapy with tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: A real-life experience
- Author
-
Tamara Chitanava, Iuliia Matvienko, Vasily Shuvaev, Sergey Voloshin, Irina Martynkevich, Yulia Vlasova, Elizaveta Efremova, Ekaterina Mileeva, Anna Pirkhalo, Taiana Makarova, Roman Vlasik, Elena Karyagina, Natalia Il`ina, Nadezhda Medvedeva, Natalia Dorofeeva, Tatiana Shneider, Nadia Siordiya, Olga Kulemina, Evgenia Sbityakova, Natalia Lazorko, Julia Alexeeva, Dmitrii Motorin, Elena Morozova, and Elza Lomaia
- Subjects
chronic myeloid leukemia ,chronic phase ,efficacy of therapy ,complete cytogenetic response ,third-line therapy ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
IntroductionTyrosine kinase inhibitor (TKI) therapy has greatly improved the prognosis of patients with chronic myeloid leukemia (CML), improving the survival expectancy of patients with chronic phase (CP) CML to that of the general population. However, despite these advances, nearly 50% of patients with CP CML experience failure to respond to frontline therapy, and most fail to respond to the subsequent second-line TKI. Treatment guidelines for patients failing second-line therapy are lacking. This study aimed to determine the efficacy of TKIs as third-line therapy in a “real-world” clinical practice setting and identify factors favorably influencing the long-term outcomes of therapy.MethodsWe have retrospectively analyzed the medical records of 100 patients with CP CML.ResultsThe median age of the patients was 51 (range, 21–88) years, and 36% of the patients were men. The median duration of the third-line TKI therapy was 22 (range, 1– 147) months. Overall, the rate of achieving complete cytogenetic response (CCyR) was 35%. Among the four patient groups with different levels of responses at baseline, the best results were achieved in the groups with any CyR at the baseline of third-line therapy. Thus, СCyR was reached in all 15 and 8/ 16 (50%) patients with partial cytogenetic response (PCyR) or minimal or minor CyR (mmCyR), respectively, whereas CCyR was detected only in 12/69 (17%) patients without any CyR at baseline (p < 0.001). Univariate regression analysis revealed that the factors negatively associated with CCyR achievement in thirdline TKI therapy were the absence of any CyR on first- or second-line TKI therapy (p < 0.001), absence of CHR prior to third-line TKI (p = 0.003), and absence of any CyR prior to third-line TKI (p < 0.001). During the median observation time from treatment initiation to the last visit [56 (4–180) months], 27% of cases progressed into accelerated phase or blast phase CML, and 32% of patients died.DiscussionProgression-free survival (PFS) and overall survival (OS) were significantly higher in patients with CCyR on third-line than in the group without CCyR on third-line therapy. At the last visit, third-line TKI therapy was ongoing in 18% of patients, with a median time of treatment exposure of 58 (range, 6–140) months; 83% of these patients had stable and durable CCyR, suggesting that patients without CHR at baseline and without CCyR at least by 12 months on third-line TKI should be candidates for allogeneic stem cell transplantation, third-generation TKIs, or experimental therapies.
- Published
- 2023
- Full Text
- View/download PDF
3. Comparative Characteristics of the Effectiveness of Tyrosine Kinase Inhibitors Vs Allogeneic Hematopoietic Stem Cell Transplantation in the Chronic Phase of Chronic Myeloid Leukemia
- Author
-
Elza Lomaia, Tamara Chitanava, Yulia Vlasova, Dmitry Motorin, Sergey Voloshin, Darina Zammoeva, Renat Badaev, Yulia Matvienko, Elizaveta Efremova, Ekaterina Mileeva, Nadia Siordia, Olga Kulemina, Eugenia Sbityakova, Natalia Lazorko, Julia Alexeeva, Irina Martynkevich, Elena Karyagina, Natalia Ilyina, Nadezhda Medvedeva, Natalia Dorofeeva, Tatiana Shneider, Svetlana Stepanova, Vasily Shuvaev, and Elena Morozova
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
4. CML-155 Prognostic Markers of the Effectiveness of Tyrosine Kinase Inhibitors in Third-Line Therapy of Chronic Phase Chronic Myeloid Leukemia Patients: Data From a Multicenter Study
- Author
-
Tamara Chitanava, Vasily Shuvaev, Iuliia Matvienko, Irina Martynkevich, Sergey Voloshin, Elizaveta Efremova, Ekaterina Mileeva, Mikhail Fominykh, Anna Kersilova, Elena Koryagina, Natalia Ilyina, Natalia Dorofeeva, Nadezhda Medvedeva, Anna Klimovich, Tatiana Shneider, Svetlana Stepanova, Natalia Polezhajkovskaya, Nadiya Siordiya, Eugenia Sbityakova, Natalia Lazorko, Elena Tochenaya, Dmitry Motorin, Nadezhda Shnalieva, Yulia Alekseeva, Darina Zammoeva, and Elza Lomaia
- Subjects
Cancer Research ,Oncology ,Hematology - Published
- 2022
5. Treatment Efficacy and Outcomes in HIV-Related Plasmablastic Lymphoma: The Results of Multicenter Retrospective Study in Russia
- Author
-
Tatiana Shneider, Vadim Baykov, Aleksandr D. Kulagin, Kirill V. Lepik, Ivan V. Tsigankov, Y. Rogacheva, Marina Demchenkova, Natalia B. Mikhailova, and M. Popova
- Subjects
medicine.medical_specialty ,Chemotherapy ,business.industry ,Bortezomib ,medicine.medical_treatment ,Immunology ,Retrospective cohort study ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Lymphoma ,Internal medicine ,Epidemiology ,medicine ,EPOCH (chemotherapy) ,business ,Prospective cohort study ,Plasmablastic lymphoma ,medicine.drug - Abstract
Background Plasmablastic lymphoma (PbL) is a rare and aggressive B-cell malignancy highly associated with HIV. Despite improved understanding of this disease, its prognosis remains poor with short overall survival. There is no standard of care for this entity. Recent advances in the treatment of HIV-associated and aggressive lymphomas have not yet significantly improved the outcomes of patients with PbL. Methods We investigate epidemiological characteristics and the results of the treatment of the HIV-related PbL in large cohort of HIV-related lymphoma patients for a 7-year period (2014-2020). During the observation period, 22 cases of HIV-related PbL were registered in three centers and selected for the analysis from the national multicenter retrospective study database. The median follow-up was 17,8 (4-57,4) months. Results The PbL accounted for 8,9% of lymphomas in HIV-infected patients (22/247). The median age was 42 years (32-61), males - 9 (41%). Most of the patients (n=19, 86%) had III-IV stages and B-symptoms were present in 8 patients (36%). CNS involvement was diagnosed in 8 patients (36%). The median of ECOG score was I (I-III). Half of patients had viral hepatitis as a co-infection including HCV (n=9), HCV and HBV (n=1), HCV, HBV and HDV (n=1). HIV and lymphoma were diagnosed simultaneously in 7 patients (32%). Median time from HIV infection to the lymphoma onset was 4 years (1,5 month - 17,5 years). The only one patient did not receive cART for an unknown reason. The median number of CD4+ cells at the moment of chemotherapy (CT) started was 151 cell/mcl (13 - 374). Frontline CT were following: CHOP±E - 9 (41%), EPOCH - 11 (50%), hyper-CVAD - 1 (4,5%), dexamethasone - 1 (4,5%). Bortezomib was added to frontline treatment in 3 (13,6%) patients, HDC with auto-HSCT had been done as a first line therapy in 2 (9%) patients. A total of 16 patients responded to the first line therapy with the overall response rate (ORR) of 72,7% including CR and PR in 4 (18,2%) and 12 (54,5%) patients respectively. Remaining patients had progression disease (n=5, 22,8%) and stable disease (n=1, 4,5%). The median course to achieve the ORR was 4 (2-6) cycles. Overall (OS) and progression-free survival (PFS) at 2 years after first line treatment was 59,1% and 40,9%, respectively. The median time to progression (TTP) was 7,95 (0,33-23,93) months. The addition of bortezomib and auto-HSCT in first line chemo improved OS (100% vs 47,1%, p=0,027), but non PFS (p=0,1) and TTP (p=0,4). Nine patients received second-line CT: DHAP - 4 (44,4%), ICE - 4 (44,4%), EPOCH - 1 (11,2%). Response was evaluated in 8 patients. CR, PR and progression disease was registered in 1 (12,5%), 2 (25%) and 5 (62,5%) patients respectively. PBSC harvesting was only successful in 1 of 3 cases (33%) and this patient received HDC with auto-HSCT. OS and PFS at 2 years after second line treatment was 44,4% and 22,2%, respectively. Two years after second line CT, 4 patients were still alive, including those after ICE, EPOCH (n=2), HDC with auto-HSCT (n=1) and nivolumab (27 cycles) as a third line therapy (n=1). Conclusions In a large cohort of patients PbL accounted for 8.9% of all HIV-related lymphomas. Bortezomib-containing chemotherapy and first line auto-HSCT show encouraging results, but data are obtained in a small group of patients. Prospective studies are needed for optimization of HIV-related plasmablastic lymphoma therapy. Disclosures No relevant conflicts of interest to declare. OffLabel Disclosure: The is early clinical date on efficiency of Bortezomib in patients with plasmablastic lymphoma: https://doi.org/10.1111/bjh.15156
- Published
- 2020
6. CML-366: Baseline Cytogenetic Response Level Impact on Survival of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors as Third-Line Therapy: Real-World Data in Five Russian Centers
- Author
-
Tamara Chitanava, Agniia-Polina Poshivay, Andrey Zaritskey, Vasily Shuvaev, Nadezhda Shnalieva, Darina Zammoeva, Mikhail Fominykh, Irina Martynkevich, Natalia Polezhajkovskaya, NT Siordiya, Eugenia Sbityakova, Anna Kersilova, Elena Koryagina, Nadezhda Medvedeva, Elena Tochenaya, Svetlana Stepanova, Natalia Ilyina, Elza Lomaia, Natalia Lazorko, Elizaveta Efremova, Olga Merzlikina, Anna Klimovich, Tatiana Shneider, and Natalia Dorofeeva
- Subjects
Cancer Research ,medicine.medical_specialty ,medicine.drug_class ,business.industry ,Ponatinib ,Context (language use) ,Hematology ,medicine.disease ,Gastroenterology ,Tyrosine-kinase inhibitor ,Dasatinib ,chemistry.chemical_compound ,Oncology ,Nilotinib ,chemistry ,Internal medicine ,medicine ,business ,Complete Hematologic Response ,Bosutinib ,medicine.drug ,Chronic myelogenous leukemia - Abstract
Context Tyrosine kinase inhibitors in third-line therapy (TKI-3L) in chronic-phase chronic myelogenous leukemia (CP CML) is effective in a portion of patients. Meanwhile, it is unclear which patients may benefit from TKI-3L. Objective To identify the factors affecting the outcome of TKI-3L therapy in CP CML. Design A retrospective study was conducted in five centers of St. Petersburg and Leningrad Region in 2019. All CP CML patients who ever obtained TKI-3L in these centers were included, except patients (pts) with complete cytogenetic response (CCyR). Results Seventy-three pts (male=26) with baseline median age 51 (25–88) were included in the study. There were 51 (70%) pts without any CyR, including 27 (37%) cases without complete hematologic response in baseline. For other patients, the best baseline cytogenetic response was minimal or minor (mmCyR) in 12 (16%) and partial (PCyR) in 10 (14%). BCR-ABL mutations were detected in 30/73 (42%) cases at any time before TKI-3L. Reasons for switching to TKI-3L were resistance in 56 (77%) or intolerance in 17 (23%). Dasatinib, Nilotinib, Bosutinib, or Ponatinib were used as TKI-3L in 43 (59%), 18 (25%), 9 (12%), and 3 (4%) pts, respectively. The median time of TKI-3L treatment duration was 15 (1–120) months. CCyR was achieved in 8/51 (16%) and 14/22 (64%) pts without CyR and with mmCyR/PCyR, respectively(p=0.001). CCyR subsequently had been lost 5/8 (62.5%) and 5/14 (29%) pts initially without or with any CyR (p=0.01). MMR was achieved in 3/51 (6%) and 6/22 (27%) pts without or with any CyR (p>0.05). Estimated overall 1-year, 3-year, and 5-year OS were 95%, 81%, and 65%, respectively. The median follow-up was 26 (3–136) months. There were 14 (19%) death: 11 due to CML progression and 3 after allo-SCT. All deaths occurred in pts without any CyR at baseline. Transformation to accelerated phase and blast crisis was occurred in 13 (18%) pts only in pts group without any CyR initially. The median time to progression was 15 (6–102) months. The only relevant baseline factor for CCyR, OS, and PFS probability in multivariant analysis was the presence of any CyR at baseline (p Conclusion Initial presence of any CyR was a favorable factor for long-term results of TKI third-line treatment in CP CML. TKI-3L should be considered as an appropriate tool in CML treatment for this group.
- Published
- 2020
7. Crude and Age-Adjusted Ph+/Bcr-Abl+ Chronic Myeloid Leukemia Incidence Rate in St. Petersburg and Leningrad Region Between 2006–2011
- Author
-
Irina Martinkevich, Natalia Ilina, Andrey Zaritskey, Elena Karyagina, Natalia Lazorko, Elza Lomaia, Elena Usacheva, Vera Udalieva, Ekaterina Romanova, Irina Zotova, Tatiana Shneider, Eugenia Sbityakova, Alla Abdulkadyrova, Vasiliy Shuvaev, Kudrat Abdulkadyrov, Elena Machulaitene, and Irina Kholopova
- Subjects
medicine.medical_specialty ,education.field_of_study ,business.industry ,Incidence (epidemiology) ,Mortality rate ,Immunology ,Population ,Age adjustment ,Cell Biology ,Hematology ,Biochemistry ,Middle age ,Transplantation ,Imatinib mesylate ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Sokal Score ,education ,business - Abstract
Abstract 4432 Background: The incidence of chronic myeloid leukemia (CML), reported from some population based registries, varies significantly. CML is known as age-dependent disease, so population age structure may strongly influent on the data. For international comparisons several systems for age-standardization are using in epidemiological studies. We conducted our retrospective study to reveal differences in CML incidence rates on the basis of calculation – crude or age-adjusted according to different population standards in St. Petersburg and Leningrad region. Methods: In 2005 the database of Ph- and/or bcr-abl- positive CML patients (pts) was conducted in St. Petersburg and Leningrad region. Since then the data from all newly diagnosed CML patients were included prospectively on population basis. The database was updated at least bi-annually. The data were obtained from hematologists, as general practitioners and private physicians are not licensed to treat oncohematological disorders. The data were double checked from the list of Imatinib distribution (the only drug reimbursed for first line treatment). To calculate crude CML incidence rate we use the data of the general census of the population in Russia in 2010 (the whole population of our region is 6596434 with population in age 15 and above 5821133). For age-adjusted CML incidence rate we use three of currently existing standards: The Segi (“World”), The Scandinavian (“European”) and the WHO standard (based on world average population between 2000–2025). Results: There are 258 (242 in chronic, 9 in accelerated and 7 in blastic phases) CML adult (15 years and above) pts, registered during 2006–2011. The median age is 53 years (48,5 and 55,5 years for men and women respectively). Sokal score was evaluable in 209 pts. It is low in 37%, intermediate in 35% and high in 28% pts. The crude CML incidence rate is slightly higher in men than in women with ratio 1,2:1. Mean annual crude CML incidence rate was 0,65 per 100 000 whole population of Saint Petersburg and Leningrad region, but it was 0,74 in adult population (15 years old and above). Mean annual CML incidence rates in the same age groups were slightly higher in all three standardized systems: 0,94 in Segi, 0,84 in Scandinavian and 0,88 in WHO standard populations. CML incidence rates in all age groups are presented in the table 1. CML incidence rate was lowest in young pts. It was unexpectedly very low in senior pts. CML incidence rates nearly for all age groups were slightly higher in St. Petersburg than in the Leningrad region. The majority of pts (98%) were treated with Imatinib (93% first or second line) or other tyrosine kinase inhibitors (5% first line-in international clinical trials, 18% after Imatinib failure or intolerance). Stem cell transplantation was performed only in 8/258 (3%) pts. Only 25235 (7,5%) evaluable pts progressed from chronic to advanced phases. Only 29/258 (11%) pts dead mostly due to CML (21 CML related deaths were reported). Estimated 5 years overall survival is 91,5%. Mean annual overall CML pts death rate was 1,9% (mean annual death rate between 2006–2010 in whole population of our region was 1,6%). Mean pts accumulated very fast - annual CML prevalence increasing rate between 2005–2011 was more than 14% (Picture 1). Conclusions: CML incidence both crude and age-adjusted in our population based registry is nearly the same in young and middle age, but much lower in senior (65 years and above) pts groups in comparison with published data from other registries which probably represents peculiarities of health system rather than real incidence. In the tyrosine kinase inhibitors era CML patients death rate is very low (nearly the same as in whole population) and CML pts is accumulated very fast in our region. Disclosures: No relevant conflicts of interest to declare.
- Published
- 2012
8. Busulfan Exposure Decrease CCyR Rate On Imatinib Therapy - Impact On Recent Pretreatment
- Author
-
Elena Koryagina, Irina Zotova, Elza Lomaia, Natalia Ilina, Vasiliy Shuvaev, Andrey Zaritskey, Zvenyslava Masliak, Irina Dyagil, Natalia Lazorko, Natalia Babkina, Irina Dmitrenko, T. Perekhrestenko, Elena Machulaitene, Svetlana Stepanova, Ekaterina Poznyak, Elena Usacheva, Kudrat Abdulkadirov, Irina Martinkevich, Eugenia Sbityakova, Ekaterina Romanova, Alla Abdulkadirova, Elena Goryunova, Maria Ivanova, Vera Udalieva, and Tatiana Shneider
- Subjects
medicine.medical_specialty ,education.field_of_study ,business.industry ,Mortality rate ,Immunology ,Population ,Myeloid leukemia ,Imatinib ,Retrospective cohort study ,Cell Biology ,Hematology ,Biochemistry ,Gastroenterology ,Surgery ,Imatinib mesylate ,Internal medicine ,medicine ,education ,Adverse effect ,business ,Busulfan ,medicine.drug - Abstract
Abstract 4452 Imatinib (IM) is now used world-wide as a first line chronic myeloid leukemia (CML) treatment. Although some time lack may exist between diagnosis and IM treatment. Earlier (Blood 2009, 114: Abstract 4278) we have shown that in CML chronic phase (CP) pts with very long history of the disease(more than five years)the pretreatment by Busulfan was the adverse prognostic factor on Imatinib therapy. Now we extend our study by a population of pts recently and for rather short time pretreated by busulfan. Aim. To investigate the effect of busulfan pretreatment on survival and responses to imatinib in CML pts in late CML CP. Materials and methods. In retrospective study 85 pts with CML CP from St-Petersburg, Leningrad region (Russian Federation) and several Ukrainian centers were included. The main inclusion criteria were: CML late CP (the duration of the disease more than 6 mos before IM start), IM therapy in routine clinical practice at least 12 months. The median time of IM therapy was 42,9 mos (12–97 mos), the median age of pts at the IM start was 49,5 years (19–83), male/female ratio 31/54. 23 patients were pretreated with busulfan (the study group) and 62 were not (control group). These groups were equal by age, sex, the median time from diagnosis to the IM start (28,3 mos in the study group and 23,9 in the control group), Sokal risk groups. Median time of busulfan pretreatment was 3,9 mos (1–62 mos). Statistical analysis was performed with SPSS 17. Results. In the whole group of patients frequency of complete cytogenetic response (CCyR) was 60% (51/85), estimated overall survival (OS) by 5 years from IM start was 87% (death rate 7% - 6/85). In the study group CCyR rate was significantly lower, than in the control group: 34,8% (8/23) and 69,35% (43/62), respectively, p=0,038. Estimated OS by 5 years was 72% (death rate 17% - 4/23) for busulfan-pretreated pts and 95% (death rate 3% - 2/62) for the control group, p Interestingly, that in the group of shortly busulfan-pretreated pts (the duration of pretreatment ≤6 mos), the lower CCyR rate has also been observed – 31% (4/13), although all other parameters were seemed equal to the control group (median time before IM start 28,3 mos). Conclusion. The pretreatment with busulfan impaired negatively the efficacy of imatinib treatment in CML late CP patients. Even short pretreatment (less than 6 mos) had adverse effect on CCyR. The mechanism is unclear. Busulfan pretreatment before imatinib therapy should not be used. Disclosures: No relevant conflicts of interest to declare.
- Published
- 2011
9. Only Time Before the Beginning of Treatment and Time to Achieve CCyR Influence the Stability of CCyR In CML-CP Patients On Imatinib Therapy
- Author
-
Dgariyat Shikhbabaeva, Elza Lomaia, Elena Usacheva, Ekaterina Romanova, Elena Machulaitene, Natalia Ilina, Irina Martynkevich, Alla Abdulkadyrova, Vasiliy Shuvaev, Evgenia Salamatova, Kudrat Abdulkadyrov, Irina Zotova, Tatiana Shneider, Vera Udalieva, Ekaterina Poznyak, Maria Ivanova, Natalia Lazorko, Elena Koryagina, Svetlana Stepanova, and Andrey Zaritskey
- Subjects
Pediatrics ,medicine.medical_specialty ,Chemotherapy ,Blast Crisis ,business.industry ,Mortality rate ,medicine.medical_treatment ,Immunology ,Interferon therapy ,Cell Biology ,Hematology ,Imatinib therapy ,medicine.disease ,Biochemistry ,Chemotherapy regimen ,medicine ,In patient ,business ,Progressive disease - Abstract
Abstract 4476 At present, the main goal of chronic myeloid leukemia (CML) therapy is to obtain complete cytogenetic response (CCyR) which is strongly associated with patient's survival. The second main factor for good prognosis after CCyR achievement is its stability. The aim of this study was to reveal factors, influencing the stability of CCyR in CML chronic phase (CML-CP) patients on Imatinib (IM) therapy in routine clinical practice. Patients and methods: In patients database of St-Petersburg and Leningrad region there are 235 CML-CP patients, who received IM for 12 months or more. Eligibility criteria for analysis were as follow: IM start dosage 400 mg/day, CCyR, which was confirmed by at least 2 consecutive cytogenetic analysis with 0% Ph+ cells in at least 20 metaphases. Patients in CCyR with IM therapy interruptions more than 3 months were censored at the date of last cytogenetic analysis. Results: 115 patients from our database were found to eligible for analysis. The median age at the diagnosis was 48 years (16-76 years). Male/female ratio was 50/65. The median time from diagnosis to IM treatment was 7 months (0.1-108 months), 55 patients begun the IM treatment in early CML-CP (≤ 6 months since diagnosis). 64, 38 and 13 patients had low, intermediate and high Sokal scores respectively. There were no differences between patients in early and late CML-CP. 56 (48,7%) patients before IM were treated with interferon. The median observation time on IM treatment was 56 months (16-88 months). Overall estimated probability of CCyR loss was 16%, rate 12.1% (14/115). In 10 patients CCyR was lost within major CyR. The estimated overall survival (all causes of death) was 78% (death rate 4.3% (5/115)), and only 1 death was CML-related. The probability of CCyR loss was not depend on previous interferon therapy and was equal in both groups -16%. The rate of CCyR loss was 15.3% (9/59) vs 8.9% (5/56) in pts with or without interferon pretreatment respectively. Sokal scores also didn't influence CCyR stability: CCyR loss rates were 10.9% (7/64), 13.2% (5/38), 15.4% (2/13) for low, intermediate and high risks, respectively (p>0.1). Probabilities of CCyR loss in different ages groups were similar: 13% (rate 8% (4/50)) vs 18% (rate 15.4% (10/65)) in patients older and younger than 50 years old, respectively (p>0.1). CCyR loss was less frequent in early CML-CP 10% (rate 3.6% (2/55)) then in late CML-CP 21% (20% (12/60)), p=0.032. For more thoroughly analysis, patients in late CML-CP were divided in subgroups related to duration of CML before IM initiation: >6 and ≤12 months, >12 and ≤60 and more than 60 months. Probabilities of CCyR loss in this groups were 22% (rate 20% (3/15)), 27% (rate 25.7% (9/35)) and 0% (rate 0% (0/10)), respectively (p Among patients, who lost CCyR, only 2/14 (14%) patients progressed to blast crisis. One of them was treated with chemotherapy followed by allo-SCT. At present, he is still alive in CCyR and complete molecular response. Another patient with blast transformation was treated by high dose IM with chemotherapy. There is no response and patient died due to progressive disease. From other patients: CCyR was re-obtained in 7 patients - in 5 patients on IM (2 pts on the same dose and 3 pts after IM dose escalation) and in 2 pts on second generation TKIs. One patient after IM dose escalation is not yet evaluable. Other 3 patients didn't respond either high dose IM or second generation TKIs, but are still alive in CML-CP. One patient lost from follow up. Conclusions: Patients in CML-CP with CCyR has very good prognosis. Very few patients progressed and dead during several years. There are two factors, which influence the probability of CCyR loss: initiation of IM in early CP and CCyR in first year of treatment are favorable to good prognosis for CCyR durability. Disclosures: No relevant conflicts of interest to declare.
- Published
- 2010
10. Experience in Second Line TKI Treatment in 6 Million Region of Russia (St-Petersburg and Leningrad region)
- Author
-
Elena Usacheva, Vasiliy Shuvaev, Elena Goryunova, Svetlana Stepanova, Ekaterina Romanova, Kudrat Abdulkadirov, Alla Abdulkadirova, Tatiana Shneider, Irina Zotova, Elena Machulaitene, Andrey Zaritskey, Ekaterina Poznyak, Eugenia Salamatova, Vera Udalieva, Elza Lomaia, Elena Koryagina, Irina Martinkevich, Natalia Ilina, and Natalija Lazorko
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Immunology ,St petersburg ,Imatinib ,Cell Biology ,Hematology ,Hematopoietic stem cell transplantation ,Biochemistry ,Imatinib resistant ,Cytogenetic Response ,Second line ,Imatinib mesylate ,Internal medicine ,medicine ,In patient ,business ,medicine.drug - Abstract
Abstract 4288 Resistance to imatinib could be overcome by new generations of TKIs. Data about the efficacy of second line TKI treatment may help to create a system for prognosing the duration of 2nd line TKI treatment and time of switching from second line TKI treatment to hematopoietic stem cell transplantation. The aim of the study was to evaluate the results of 2nd line TKI treatment in patients resistant or intolerant to imatinib. Patients and methods 44 resistant and 3 intolerant to imatinib pts were included. Cytogenetics with G-banding and PCR with sequencing were performed for evaluation the response and mutations. There were 39, 7 and 1 pts in CP, AP and BP respectively, Patients were treated by three different ATP-pocket inhibitors. The follow-up on 2nd line TKIs was 0.9-48mons (Median - 15.9 mons), median follow-up from diagnosis was 73,9 mons. In prognosis analysis (CHR, cytogenetics, Sokal) intolerant patients were not included. Results Probability of overall survival from diagnosis by 10 years was 85%. Probability of survival from the start of TKI2 by 4 y -90%. There were no differences in survival in pts with primary and secondary resistance, in CP and AP. Patients with low and intermediate Sokal risk did better than patients with high risk (p=0.014, Fig. 1.). 8 pts had T315I mutation when studied on second line TKI therapy. Achievement of CCyR was 50% (58% when T3151 patients were excluded), it was higher in low+intermediate in comparison with high risk pts (60% vs 30%, p=0.091), in CP than in AP (56% vs 20%,p=0.07), in patients with CHR at switching than in those without CHR (72% vs 18%, p=0.014). We failed to find any differences in CCyR achievement in pts with different best cytogenetic response on imatinib (complete, major, minor, minimal responses, absence of cytogenetic response). MCyR depended on the type of resistance - it was higher in secondary, than in primary resistant pts (80% vs 45%,p=0.06, Fig2). Probability of MCCyR loss was 20%, all of them appear during the first year of treatment. It was higher in AP than in CP (40% vs 12%,P=0.04). Probability of 4 years PFS was high - 75%, also without differences in primary vs secondary resistance and even in AP vs CP. Conclusion Second line TKI treatment is very efficacious in imatinib resistant pts. The effect depended on the type of resistance and phase of the disease, CHR at the moment of switching to 2nd line treatment. Disclosures: No relevant conflicts of interest to declare.
- Published
- 2009
11. 6 Year Experience of Treatment by Imatinib in CML CP Patientsin 6 Million Population Region of Russia(Saint-Petersburg and Leningrad region)with Impact On Time and Kind of Pretreatment
- Author
-
Natalia Ilina, Natalija Lazorko, Elena Goryunova, Irina Zotova, Vasiliy Shuvaev, Elza Lomaia, Tatiana Shneider, Elena Koryagina, Vera Udalieva, Eugenia Salamatova, Elena Machulaitene, Kudrat Abdulkadirov, Elena Usacheva, Irina Martinkevich, Ekaterina Romanova, Alla Abdulkadirova, Andrey Zaritskey, Svetlana Stepanova, and Ekaterina Poznyak
- Subjects
medicine.medical_specialty ,education.field_of_study ,business.industry ,Immunology ,Population ,Imatinib ,Cell Biology ,Hematology ,Biochemistry ,Gastroenterology ,Imatinib mesylate ,Internal medicine ,medicine ,In patient ,Saint petersburg ,Good prognosis ,education ,Sokal Score ,business ,Busulfan ,medicine.drug - Abstract
Abstract 4278 Imatinib(IM) has become the “gold standard” for the treatment of CML CP. In clinical trials the majority of pts obtain complete hematologic (CHR) and complete cytogenetic (CCyR) responses. The aim of the study was to evaluate the results of treatment by IM in CML CP pts in general practice (outside clinical trials). Patients and methods There are 335 pts with CML in databases in Saint-Petersburg and Leningrad region. Most of them (283/335-84,5%) are ever treated with IM. Disease phases at the time of the start of IM therapy by ELN (from 268/283 evaluable pts) and MDACC (from 256/283 evaluable pts) criteria were: CP – 232 and 215, AP – 28 and 33, BP - 8 and 8 respectively. All 232 pts in CML CP (by ELN criteria) treated since 2001 by IM were included in the study. Before IM 91/232(39%), 114/232(49%) and 17/232 (7,3%) pts were pretreated by hydroxyurea, interferon-alfa with or without hydroxyurea and busulfan. 12/335(4%) pts were undergone alloSCT(6 alive, 6 dead due to progression or TRM) There were 134/232(58%) pts in early (duration before Im ≤ 12 mos) and 98/232(42%) pts in late CP (> 12 mos). In early and late CP, there were 49/123 and 50/89, 40/123 and 23/89, 34/123 and 16/89 evaluable pts with low, intermediate and high Socal score respectively. The predominance of low Sokal score in late CP pts could to be related to survival benefit before imatinib.. The median time before Im for the whole group, for early and late CP pts were 7,4 mos(from 7 days to 132 mons), 1,8 mons (form 7 days to 12 mons) and 39 mons (from 12,1 mos to 132 mos) respectively. Median time of Im therapy was 33 mos (1 - 75 mos) in whole group, 24mons (1 - 73mos) in early and 34mos(2 - 75mos) in late CP pts respectivel Results Estimated overall survival by 6 years was 94,2% in whole group, 97% and 87% in early and late CP pts resp. Only 14/228(6,1%) of evaluable patients died due to CML: 4/130(3%) in early and 10/98(10,2%) in late CP group. 4 pts, resistant to IM, were transplanted: 1 in early CP and 3 in BP. Deathes were due to TRM or disease progression. CHR was achieved by 3 mons in most cases: 82/110(74,5%) and 36/64(56%) pt, in early and late CP, resp. Patients (39 in hole group, 12 in early and 27 in late CP) with CHR before IM were excluded from these analyses. The probability of CCyR by 6 years was 98% in early CP and 82% in late CP (p=0.002). The rate of CCyR was 75% 80/107) vs 31% (14/75) in patients with or without CHR by 3 mons (p=0.00). The same differences were found in early and late CP. CCyR in patients with CHR before IM was the same as in patients with newly obtained CHR by 3 mons on IM. Thereafter we have divided group of pts with late CP according to its duration before IM (very early - Achievement of CCyR was higher in pts in very early(69.1%) and early –late(68.2%) than in very late group(34.6%)(p=0.09) Further subdivisions of the period of 6-60 mos did not reveal any differences. Moreover, when we deleted the patients pretreated with busulfan, the differences were found only between early and early-late phases. We have separately analyzed very late group, it appeared that pretreatment with busulfan severely decreases CCyR (22% vs 81% in with (12 pts) or without (7 pts) busulfan pretreatment, p=0,002. Probably, patients in very late CP is a specific group of patients with preformed very good prognosis. Clonal evolution before treatment (8 pts in early CP and 7 in late CP) did not influence CCyR achievement. The probability of progression to AP/BP was slightly higher in late (6%) than in early CP (3%) (p=0.05). The appearance of clonal evolution was higher in late than in early CP (p=0,0002). Progression to AP/BP was 1% vs 11% in pts with or without CHR by 3 mos resp. (p=0.003). Conclusions Imatinib is efficacious drug in general hematological practice with very high probability of overall survival, CCyR and low risk of progression to AP/BP. CHR is an early and very important predictor for further successful treatment. Achievement of CCyR strongly depends on CHR by 3 mons. Patients with CHR before imatinib have similar CCyR in patients with CHR by 3 mons on imatinib. Pretreatment period predispose patients to clonal evolution on imatinib treatment. Busulfan pretreatment severely decreases probability of CCyR. Disclosures: No relevant conflicts of interest to declare.
- Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.